Orakl Oncology

Orakl Oncology operates an AI-powered drug discovery platform that utilizes a proprietary dataset of patient-derived tumor organoids enriched with genomic, transcriptomic, and clinical data. The company provides biopharmaceutical partners with predictive tools to identify therapeutic targets and anticipate clinical trial outcomes, such as patient response and survival rates. Their technology specifically targets drug development for colorectal, pancreatic, and KRAS-mutant cancers.